{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:26:31Z","timestamp":1752549991472},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T00:00:00Z","timestamp":1394064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10928-014-9350-8","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T11:47:28Z","timestamp":1394020048000},"page":"109-125","source":"Crossref","is-referenced-by-count":6,"title":["Concordance between criteria for covariate model building"],"prefix":"10.1007","volume":"41","author":[{"given":"Stefanie","family":"Hennig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,6]]},"reference":[{"issue":"4","key":"9350_CR1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10928-007-9057-1","volume":"34","author":"J Ribbing","year":"2007","unstructured":"Ribbing J, Nyberg J, Caster O, Jonsson EN (2007) The lasso\u2014a novel method for predictive covariate model building in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn 34(4):485\u2013517","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"9350_CR2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1208\/s12248-011-9289-2","volume":"13","author":"A Khandelwal","year":"2011","unstructured":"Khandelwal A, Harling K, Jonsson EN, Hooker AC, Karlsson MO (2011) A fast method for testing covariates in population PK\/PD Models. AAPS J 13(3):464\u2013472","journal-title":"AAPS J"},{"key":"9350_CR3","unstructured":"FDA (1999) Guidance on population pharmacokinetics. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072137.pdf"},{"key":"9350_CR4","unstructured":"EMEA European Medicines Agency (2007) Guidline on reporting the results of population pharmacokinetic analyses Doc.Ref. CHMP\/EWP\/185990\/06"},{"issue":"3","key":"9350_CR5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1011579109640","volume":"28","author":"KG Kowalski","year":"2001","unstructured":"Kowalski KG, Hutmacher MM (2001) Efficient screening of covariates in population models using Wald\u2019s approximation to the likelihood ratio test. J Pharmacokinet Pharmacodyn 28(3):253\u2013275","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9350_CR6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10928-006-9004-6","volume":"33","author":"RR Bies","year":"2006","unstructured":"Bies RR, Muldoon MF, Pollock BG, Manuck S, Smith G, Sale ME (2006) A genetic algorithm-based, hybrid machine learning approach to model selection. J Pharmacokinet Pharmacodyn 33(2):195\u2013221. doi: 10.1007\/s10928-006-9004-6","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"9350_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","volume":"28","author":"U W\u00e4hlby","year":"2001","unstructured":"W\u00e4hlby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28(3):231\u2013252","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9350_CR8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2125.2007.03045.x","volume":"65","author":"S Hennig","year":"2008","unstructured":"Hennig S, Norris R, Kirkpatrick CM (2008) Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis\u2013a population pharmacokinetic study. Br J Clin Pharmacol 65(4):502\u2013510","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9350_CR9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00280-005-0140-2","volume":"58","author":"M Sandstrom","year":"2006","unstructured":"Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58(2):143\u2013156","journal-title":"Cancer Chemother Pharmacol"},{"key":"9350_CR10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1475-2875-8-304","volume":"8","author":"B Tan","year":"2009","unstructured":"Tan B, Naik H, Jang IJ, Yu KS, Kirsch LE, Shin CS, Craft JC, Fleckenstein L (2009) Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malar J 8:304","journal-title":"Malar J"},{"issue":"4","key":"9350_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200948040-00003","volume":"48","author":"EI Nielsen","year":"2009","unstructured":"Nielsen EI, Sandstrom M, Honore PH, Ewald U, Friberg LE (2009) Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet 48(4):253\u2013263","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"9350_CR12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2125.2008.03281.x","volume":"66","author":"AF Hawwa","year":"2008","unstructured":"Hawwa AF, Collier PS, Millership JS, McCarthy A, Dempsey S, Cairns C, McElnay JC (2008) Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol 66(6):826\u2013837","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"9350_CR13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","volume":"21","author":"MO Karlsson","year":"1993","unstructured":"Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21(6):735\u2013750","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"9350_CR14","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/BF01064424","volume":"20","author":"R Bruno","year":"1992","unstructured":"Bruno R, Iliadis MC, Lacarelle B, Cosson V, Mandema JW, Le Roux Y, Montay G, Durand A, Ballereau M, Alasia M et al (1992) Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. J Pharmacokinet Biopharm 20(6):653\u2013669","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"9350_CR15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic\u2013pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20(5):511\u2013528","journal-title":"J Pharmacokinet Biopharm"},{"issue":"18","key":"9350_CR16","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-06-0815","volume":"12","author":"C Kloft","year":"2006","unstructured":"Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clinical Cancer Res 12(18):5481\u20135490","journal-title":"Clinical Cancer Res"},{"issue":"24","key":"9350_CR17","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2002","unstructured":"Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713\u20134721","journal-title":"J Clin Oncol"},{"issue":"2","key":"9350_CR18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1020561807903","volume":"26","author":"MO Karlsson","year":"1998","unstructured":"Karlsson MO, Jonsson EN, Wiltse CG, Wade JR (1998) Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 26(2):207\u2013246","journal-title":"J Pharmacokinet Biopharm"},{"key":"9350_CR19","volume-title":"NONMEM User\u2019s Guides. (1989\u20132009)","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM User\u2019s Guides. (1989\u20132009), 7th edn. Icon Development Solutions, Ellicott City, MD","edition":"7"},{"issue":"3","key":"9350_CR20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241\u2013257","journal-title":"Comput Methods Programs Biomed"},{"issue":"4","key":"9350_CR21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-012-9256-2","volume":"39","author":"CV Lagishetty","year":"2012","unstructured":"Lagishetty CV, Vajjah P, Duffull SB (2012) A reduction in between subject variability is not mandatory for selecting a new covariate. J Pharmacokinet Pharmacodyn 39(4):383\u2013392","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9350_CR22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2125.2004.02170.x","volume":"58","author":"U W\u00e4hlby","year":"2004","unstructured":"W\u00e4hlby U, Thomson A, Milligan P, Karlsson M (2004) Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmaco 58(4):367\u2013377","journal-title":"Br J Clin Pharmaco"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-014-9350-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-014-9350-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-014-9350-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:04:06Z","timestamp":1559451846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-014-9350-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,6]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["9350"],"URL":"https:\/\/doi.org\/10.1007\/s10928-014-9350-8","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,6]]}}}